Recent developments in inflammatory bowel disease.
The evolving medical armamentarium holds promise for more precise and effective therapies for IBD. The experience with anti-TNF therapy, particularly infliximab, illustrates the potential efficacy of therapies targeted at specific mediators or pathways involved in the pathogenesis. Advances in molecular technology have enabled the development of novel and potentially effective targeted therapies. Equally important is the increasing scientific understanding of the pathogenesis of IBD, which will likely improve the ability to stratify disease and to select therapies based on genotypic, immunologic, and phenotypic profiles in the future.
Su
Chinyu
C
Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Third Floor Ravdin Building, 3400 Spruce Street, Philadelphia, PA 19104-4283, USA.
Lichtenstein
Gary R
GR
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000235:genetics*; D003424:Crohn Disease / Q000188:drug therapy* / Q000235:genetics*; D016572:Cyclosporine / Q000627:therapeutic use; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D015122:Mercaptopurine / Q000627:therapeutic use; D012460:Sulfasalazine / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D005938:Glucocorticoids; D014409:Tumor Necrosis Factor-alpha; C402162:CDP 571; D012460:Sulfasalazine; D016572:Cyclosporine; D000069285:Infliximab; D015122:Mercaptopurine